Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEAMERICAN:LCTXTSE:VSN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLCTXLineage Cell Therapeutics$1.01-1.0%$0.67$0.37▼$1.15$232.92M1.61.59 million shs912,561 shsVSNVeresenC$0.00C$11.40▼C$19.07C$5.81BN/A1.30 million shs1.15 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLCTXLineage Cell Therapeutics+13.62%-4.67%+53.38%+144.43%+2.28%VSNVeresen0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationLCTXLineage Cell Therapeutics2.8287 of 5 stars3.51.00.00.02.73.30.6VSNVeresenN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLCTXLineage Cell Therapeutics 3.00Buy$4.20315.84% UpsideVSNVeresen 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest VSN and LCTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/23/2025LCTXLineage Cell TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$2.006/23/2025LCTXLineage Cell TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLCTXLineage Cell Therapeutics$9.50M24.28N/AN/A$0.35 per share2.89VSNVeresenN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLCTXLineage Cell Therapeutics-$18.61M-$0.12N/AN/AN/A-169.57%-22.64%-15.27%8/6/2025 (Estimated)VSNVeresenN/AN/A0.00N/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLCTXLineage Cell TherapeuticsN/AN/AN/AN/AN/AVSNVeresenC$1.005.27%N/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLCTXLineage Cell TherapeuticsN/A3.823.82VSNVeresenN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLCTXLineage Cell Therapeutics62.47%VSNVeresenN/AInsider OwnershipCompanyInsider OwnershipLCTXLineage Cell Therapeutics26.80%VSNVeresenN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLCTXLineage Cell Therapeutics60228.36 million167.16 millionNot OptionableVSNVeresen147,000314.00 millionN/ANot OptionableVSN and LCTX HeadlinesRecent News About These CompaniesJordan Cove parent company looks at financing, ownership options, expansionSeptember 28, 2023 | theworldlink.comTELD apologises after nearly 10,000 voters in Tanjong Pagar GRC receive two poll cards due to printer’s errorAugust 27, 2023 | channelnewsasia.comCJordan Cove donates more than $300,000 to defeat measureMay 22, 2023 | theworldlink.comTEncuentran al menos 60 cadáveres en provincia del Congo - ChronApril 26, 2023 | news.google.comNVeresen (TSE:VSN) Stock Price Passes Above Two Hundred Day ... - Defense WorldApril 18, 2023 | news.google.comNOregon DEQ opens comments on permit renewal for former Weyerhaeuser facilityApril 11, 2023 | theworldlink.comTBidders Can Structure Offers To Discourage The Use Of Rights Of ... - Mondaq News AlertsApril 5, 2023 | news.google.comNRecuperan 36 cadáveres en un pozo tras derrumbe en India - Hartford City News TimesMarch 31, 2023 | news.google.comNThe Right Of First Refusal And Good Faith In Your Business Contract ... - Mondaq News AlertsMarch 29, 2023 | news.google.comNBidders can Structure Offers to Discourage the Use of Rights of First ... - LexologyMarch 28, 2023 | news.google.comNPembina Pipeline : Gas Infrastructure - Marketscreener.comMarch 27, 2023 | news.google.comNBidders can Structure Offers to Discourage the Use of Rights of First ... - McMillan LLPMarch 27, 2023 | news.google.comNBBC Sounds - Assignment - Available EpisodesMarch 25, 2023 | bbc.co.ukThe Right of First Refusal and Good Faith in Your Business Contract ... - LexologyMarch 21, 2023 | news.google.comNLiquefied Natural Gas Market to See Massive Growth by 2029 ... - Digital JournalMarch 14, 2023 | news.google.comNNatural Gas Market Booming Worldwide( Forecast Period 2023-2029) With Top Player:BG Group plc, Apache Corporat - openPRMarch 14, 2023 | news.google.comNLong-term supply agreements and high inflation — what businesses ... - McCarthy Tétrault LLPMarch 9, 2023 | news.google.comNCEN: Reasonable CEF, But The Private Position Could Be A ... - Seeking AlphaMarch 8, 2023 | news.google.comNInsights and Takeaways From Our Top 10 Commercial Litigation ... - LexologyFebruary 28, 2023 | news.google.comNGlobal Natural Gas Market Industry Analysis, Size, Share, Demand ... - Taiwan NewsFebruary 27, 2023 | news.google.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVSN and LCTX Company DescriptionsLineage Cell Therapeutics NYSEAMERICAN:LCTX$1.01 -0.01 (-0.98%) As of 05:00 PM EasternLineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.Veresen TSE:VSNVeresen Inc is a Canada-based energy infrastructure company that owns and operates energy infrastructure assets across North America. The Company is engaged in three principal businesses: a pipeline transportation business consists of interests in the Alliance Pipeline, the Ruby Pipeline and the Alberta Ethane Gathering System (AEGS); a midstream business, which includes a partnership interest in Veresen Midstream Limited Partnership, which owns assets in western Canada, and an ownership interest in Aux Sable, which owns a natural gas liquids (NGL) extraction facility near Chicago, and other natural gas and NGL processing energy infrastructure, and a power business consists of a portfolio of assets in Canada. The Company's segments include Pipelines, Midstream, Power and Corporate. Alliance Pipeline owns and manages an integrated, high-pressure natural gas and NGL pipeline. Ruby Pipeline is a natural gas transmission system. AEGS is an integrated pipeline system. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Nike's Stock Just Got an Upgrade: Is a Real Comeback Brewing? Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
